NSC12
NSC12 is an orally active pan-FGF trap. NSC12 inhibits the interaction between FGF2/FGFR. NSC12 suppresses the phosphorylation of FGFR3. NSC12 reduces c-Myc levels, induces DNA damage, triggers the cleavage of Caspase 3, and promotes ROS production. NSC12 exhibits anticancer activity against lung cancer and multiple myeloma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 102586-30-1
- Formule: C24H34F6O3
- Masse moléculaire:484.52
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis
MoreVoir tous les produits spécifiques à Isoform Caspase
More
Activité biologique
|
Caspase 3 |
FGFR3 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO-K1 | IC50 |
10 μM
Compound: 11
|
Inhibition of human recombinant FGF2 assessed as reduction in HSPG/FGF2/FGDR interaction by measuring FGF2 mediated A475-CHO-flg-1A-luc cell to CHO-K1 cell adhesion incubated for 2 hrs by luciferase assay
Inhibition of human recombinant FGF2 assessed as reduction in HSPG/FGF2/FGDR interaction by measuring FGF2 mediated A475-CHO-flg-1A-luc cell to CHO-K1 cell adhesion incubated for 2 hrs by luciferase assay
|
[PMID: 27138345] |
| KMS-11 | IC50 |
3.4 μM
Compound: 1; NSC12
|
Antiproliferative activity against human KMS-11 cells assessed as reduction in cell viability incubated for 48 hrs by propidium iodide staining-based flow cytometric analysis
Antiproliferative activity against human KMS-11 cells assessed as reduction in cell viability incubated for 48 hrs by propidium iodide staining-based flow cytometric analysis
|
[PMID: 34004471] |
| Lewis lung carcinoma cell line | IC50 |
2 μM
Compound: 11
|
Antiproliferative activity against mouse LLC cells incubated for 48 hrs by PI-staining based flow cytometry
Antiproliferative activity against mouse LLC cells incubated for 48 hrs by PI-staining based flow cytometry
|
[PMID: 27138345] |
| NCI-H520 | IC50 |
4.1 μM
Compound: 11
|
Antiproliferative activity against human NCI-H520 cells incubated for 72 hrs by PI-staining based flow cytometry
Antiproliferative activity against human NCI-H520 cells incubated for 72 hrs by PI-staining based flow cytometry
|
[PMID: 27138345] |
NSC12 (0.3-10.0 μM; 48 h for LLC cells, 72 h for H520 cells) inhibits the proliferation of mouse Lewis lung carcinoma (LLC) cells and H520 lung cancer cells, with an IC50 of 2.0 μM for the former and 4.1 μM for the latter[1].
NSC12 (6 μM; 6 h) inhibits FGFR3 phosphorylation by 75% in multiple myeloma KMS-11 cells treated with 6 μM NSC12 for 6 h[2].
NSC12 (6 μM; 6 h) inhibits FGFR phosphorylation in multiple myeloma cell lines KMS-11, OPM-2, U-266, and the Bortezomib-resistant strain KMS-11/BTZ[2].
NSC12 (6 μM; 6 h) reduces c-Myc levels and induces DNA damage in multiple myeloma KMS-11 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:murine Lewis lung carcinoma (LLC) cells, human H520 lung carcinoma cells
-
Concentration:0.3-10.0 μM
-
Incubation Time:48 h (LLC cells); 72 h (H520 cells)
-
Result:Efficiently impaired proliferation of both FGF-dependent cell lines, with an IC50 of 2.0 μM for LLC cells and 4.1 μM for H520 cells.
-
Cell Line:human multiple myeloma KMS-11 cells (t(4;14) translocation, FGFR3 overexpression)
-
Concentration:6 μM
-
Incubation Time:6 h
-
Result:Inhibited FGFR3 phosphorylation by 75%.
-
Cell Line:human multiple myeloma cell lines KMS-11, OPM-2, U-266, and bortezomib-resistant KMS-11/BTZ
-
Concentration:0.1-10.0 μM
-
Incubation Time:48 h
-
Result:Inhibited cell viability with the following half-maximal inhibitory concentrations (IC50): 3.6 μM (KMS-11), 4.4 μM (OPM-2), 3.4 μM (U-266), 3.6 μM (KMS-11/BTZ).
-
Cell Line:human multiple myeloma KMS-11 cells
-
Concentration:6 μM
-
Incubation Time:6 h
-
Result:Strongly reduced c-Myc protein levels.
Increased γH2AX (DNA damage marker) levels.
Induced cleavage of caspase 3 (apoptosis marker).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD/SCID (female, 6-8-week-old)[2]
-
Dosage:7.5 mg/kg
-
Administration:i.p.; every other day
-
Result:Reduced tumor growth by approximately 40% compared to vehicle control.
Lowered tumor weight significantly compared to vehicle control.
Inhibited tumor FGFR phosphorylation.
Reduced c-Myc protein levels.
Increased tissue oxidative stress (nitrotyrosine staining).
Increased DNA damage (γH2AX staining).
Reduced tumor cell proliferation (pHH3 staining).
Increased apoptotic cell death (cleaved caspase 3 staining).
Caused no significant changes in mouse body weight, blood cell composition, blood biochemical parameters, or blood phosphorus/calcium levels.
Chemical Information
-
CAS No. 102586-30-1
-
Appearance Solid
-
Masse moléculaire 484.52
-
Formule C24H34F6O3
-
Color White to light yellow
-
SMILES
C[C@@]12[C@](CC[C@]2([H])[C@@H](O)CC(C(F)(F)F)(O)C(F)(F)F)([H])[C@@]3([H])[C@@](CC1)([H])[C@@]4(C(C[C@H](CC4)O)=CC3)C
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 10 mg/mL (20.64 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (536 KB)
- English - EN (536 KB)
- Français - FR (536 KB)
- Deutsch - DE (536 KB)
- Norwegian - NO (536 KB)
- Español - ES (536 KB)
- Swedish - SV (536 KB)
- Italian - IT (536 KB)
- Korean - KR (536 KB)
- Portuguese - PT (536 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Castelli R, et al. Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors. J Med Chem. 2016;59(10):4651-4663. [Content Brief]
[2]. Taranto S, et al. Discovery of novel FGF trap small molecules endowed with anti-myeloma activity. Pharmacol Res. 2024;206:107291. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0639 mL | 10.3195 mL | 20.6390 mL | 51.5975 mL |
| 5 mM | 0.4128 mL | 2.0639 mL | 4.1278 mL | 10.3195 mL | |
| 10 mM | 0.2064 mL | 1.0319 mL | 2.0639 mL | 5.1597 mL | |
| 15 mM | 0.1376 mL | 0.6880 mL | 1.3759 mL | 3.4398 mL | |
| 20 mM | 0.1032 mL | 0.5160 mL | 1.0319 mL | 2.5799 mL |
NSC12 Related Classifications
HY-107194 Related Classifications
Powered by Bioz